BIO applauds introduction of the PARTNER Act.
Share:
Press Release Summary:
BIO applauds Rep. Pat Meehan (R-PA) for introducing the Partnerships to Advance Revolutionary Technology and Novel Entrepreneurial Research (PARTNER) Act (H.R. 2179). Bill would allow companies to partner with their investors on a specific research project or pipeline. Only start-up and small companies dedicated to R&D would be eligible to use these R&D Partnership Structures, so investors would be incentivized to invest at an earlier stage when capital is most needed.
Original Press Release:
BIO Applauds Introduction of the PARTNER Act to Stimulate Investment in Innovation
WASHINGTON--Today, the Biotechnology Industry Organization (BIO) applauds Rep. Pat Meehan (R-PA) for introducing the Partnerships to Advance Revolutionary Technology and Novel Entrepreneurial Research (PARTNER) Act (H.R. 2179). The bill is co-sponsored by Reps. Richard Neal (D-MA), Mike Kelly (R-PA), Ron Kind (D-WI) and John Larson (D-CT). The bill would support early-stage research by incentivizing investment in R&D-focused small businesses.
“We commend Reps. Meehan, Neal, Kelly, Kind, and Larson and look forward to working with the Congress to pass this critical legislation.”
The PARTNER Act would allow companies to partner with their investors on a specific research project or pipeline. Only start-up and small companies dedicated to R&D would be eligible to use these R&D Partnership Structures, so investors would be incentivized to invest at an earlier stage when the capital is most needed.
The following can be attributed to Jim Greenwood, BIO’s President and CEO:
“We strongly support this legislation that has been designed to help drive private investment dollars to emerging biotech companies working on breakthrough treatments and cures for suffering patients.
“Conducting groundbreaking research is a decades-long, billion-dollar endeavor, and emerging companies desperately need early-stage investors with a long-term investment strategy. This bill would encourage capital formation to support early stage R&D.
“Pre-revenue companies often do not benefit from the existing innovation incentives in the tax code, but the PARTNER Act would support their research to ensure that small companies receive the funding necessary to serve patients that are waiting on breakthrough treatments and cures to address the most life-threatening and devastating diseases.
“We commend Reps. Meehan, Neal, Kelly, Kind, and Larson and look forward to working with the Congress to pass this critical legislation.”
For more information on BIO and the biotechnology industry organization, please visit www.bio.org.
About BIO
BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling “innovations transforming our world” and the BIO Newsletter is the organization’s bi-weekly email newsletter. Subscribe to the BIO Newsletter.
Upcoming BIO Events
BioEquity Europe
May 19-20, 2015
Vienna, Austria
BIO Executive Training Courses
June 13-15, 2015
Philadelphia, PA
BIO International Convention
June 15-18, 2015
Philadelphia, PA
World Congress on Industrial Biotechnology
July 19-22, 2015
Montréal, Canada
BIO Latin America Conference
October 14-16, 2015
Rio de Janeiro, Brazil
BIO Investor Forum
October 20-21, 2015
San Francisco, CA
Contacts
Biotechnology Industry Organization (BIO)
Tracy Cooley, APR, 202-312-9274
Web: www.bio.org
Blog: www.biotech-now.org
Twitter: @IAmBiotech
